Seres Therapeutics Inc (NAS:MCRB)
$ 0.7589 -0.017 (-2.19%) Market Cap: 114.94 Mil Enterprise Value: 221.66 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 49/100

Seres Therapeutics Inc at Canaccord Genuity Growth Conference Transcript

Aug 09, 2023 / 07:00PM GMT
Release Date Price: $4.03 (-6.06%)
John Newman
Canaccord Genuity Group Inc. - Analyst

Good afternoon, everybody. Thanks for joining us at the 43rd Annual Canaccord Genuity Growth Conference this afternoon. I'm John Newman. I'm one of the senior biotech analysts here at Canaccord and really excited to have I'm Eric Shaff, the CEO of Seres Therapeutics with us today. So Seres has a very unique therapy for C. difficile and are developing microbiome therapies and other areas. So Eric?

Eric Shaff
Seres Therapeutics, Inc. - President & CEO

Well, good afternoon, everybody. And thank you, John, and thanks to Canaccord for having us here to present at this year's conference. We think it's a great time to connect with you with the opportunity to talk about Seres, the opportunity to talk about the microbiome, our progress in 2023, and I think as importantly, the future of the microbiome space, and importantly, the future of patients that can be helped with microbiome therapeutics.

We think that in any new modality or medical area, there can be the hope or the promise or even an aspiration

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot